New method identifies antibody-like proteins with diagnostic and therapeutic potential for SARS-CoV-2

Scienmag

Antibody-like proteins that capture and neutralize SARS-CoV-2 Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus – 4 of which also exhibited neutralizing activity – within 4 days, according to a new study.

A protein-based COVID-19 vaccine that mimics the shape of the virus

The Pharma Data

Now, researchers reporting in ACS Central Science have immunized mice with nanoparticles that mimic SARS-CoV-2 by displaying multiple copies of the receptor binding domain (RBD) antigen, showing that the vaccine triggers robust antibody and T cell responses.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Is Cell-Based Fish the Next Big Food Innovation?

XTalks

We’ve heard of cell-based meat — meat produced by in vitro cell cultures of animal cells — but its seafood equivalent could be on the horizon. To produce cell-based fish, muscle cells from a fish are extracted and propagated in ideal conditions inside a bioreactor.

Oncotarget: mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC

Scienmag

All these preclinical data strongly suggest that the inhibition of mTORC1 and PLK1 proteins may be a promising therapeutic approach for NSCLC patients Credit: Correspondence to – Didier Decaudin – Didier.decaudin@curie.fr

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

Pharma Mirror

1] It became continually challenging in targeting KRAS transformation bearing tumors in view of the unclear construction of the protein, however by a wide margin but AMG 510, an effective inhibitor was brought into these clinical preliminaries. [2]

EVOTEC EXPANDS OXFORDSHIRE SITE INTO A FULLY-INTEGRATED R&D CENTRE NAMED ‘DOROTHY CROWFOOT HODGKIN CAMPUS’

BioTech 365

CREATES UNIQUE CO-LOCATED, FULLY-INTEGRATED, HIGH-CAPACITY R&D CENTRE ADDS IN VITRO PHARMACOLOGY AND EXPANDS PROTEIN SCIENCES CREATES CENTRE OF EXCELLENCE … Continue reading → EQS NewsfeedDGAP-News: Evotec SE / Key word(s): Miscellaneous 12.11.2020 / 07:30 The issuer is solely responsible for the content of this announcement.

Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types

The Pharma Data

The Elecsys Anti-p53 could be used to monitor cancer cell remnants in the patient’s body. today announced the launch of the Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies.

Gilead says Veklury should work against COVID-19 variants

Pharma Phorum

Gilead Sciences says its antiviral Veklury should be effective against the new, more contagious COVID-19 variants discovered in the UK and South Africa.

Parkinson’s and Melanoma Share an Amyloid Link, Says New Research

XTalks

synuclein, a protein involved in the formation of amyloid deposits in the brain characteristic of Parkinson’s disease and other neurodegenerative disorders, is also implicated in melanoma. Related: 6 Parkinson’s Biotech Companies: Where Are They in 2021?

JS Bio and Etta Biotech Advancing Strategic Partnership

The Pharma Data

Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. With its excellent electroporation technology and equipment, Etta Biotech has become a world leader in its field.

Are All Excipients Truly Inert? Maybe Not, Suggests New Study

XTalks

Excipients can take many forms, such as bulking agents, binders, coatings and colourants, and they are chosen based on their ability to aid in drug delivery, administration and even in pill identification and prevention of counterfeiting.

How Nanobodies from Cormac the Llama Could Prevent COVID-19 Infection

XTalks

Researchers at the National Institutes of Health (NIH) in the US have isolated small antibodies called “nanobodies” from a llama named Cormac that can block the SARS-CoV-2 coronavirus. Preliminary results from the study were published in the journal Scientific Reports.

New FDA Guidances for August 2020 and Upcoming Advisory Committee Meetings

CATO Research

Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation: Draft Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders – Draft Guidance.

Moderna’s COVID-19 Vaccine Effective Against New Variants

XTalks

The company used in vitro neutralization antibody studies to evaluate the activity of Moderna’s vaccine-generated antibodies in human sera against several variants of the novel coronavirus, including the B.1.1.7

Roche introduces 15-minute nasal COVID test in UK

Pharma Phorum

Roche Diagnostics has launched a 15-minute nasal antigen test for COVID-19 in the UK, and says it has millions of the kits available straight away to help the country recover from the pandemic. . The post Roche introduces 15-minute nasal COVID test in UK appeared first on.

SKUP Reports Positive Evaluation of the LumiraDx SARS-CoV-2 Antigen Test in Symptomatic and Asymptomatic Patients

The Pharma Data

In a mixed population of symptomatic and asymptomatic subjects tested in point of care settings, the test achieved 87-90% agreement with RT-PCR which increased to 92-95% in patients with viral load corresponding to Ct below 33. in nasal swab specimens. LONDON , Jan.

AbbVie Snatches Up Antibody from Harbour BioMed to Fight COVID-19 and Related Mutations

The Pharma Data

AbbVie has initiated a Phase I clinical trial of the antibody, and it will conduct the initial clinical program in the U.S. The antibody targets a specific conserved region of the SARS-CoV-2 spike protein. Specifically, it is being examined in adults who are hospitalized with COVID-19.

FDA Action Alert: Urovant, Athenex, scPharmaceuticals and Vertex

The Pharma Data

The data supported the potential benefits of the drug for OAB in patients with urge urinary incontinence (UUI), urgency, and urinary frequency. Athenex and Almirall have a license deal with Almirall having the license to research, develop and commercialize the drug in the U.S. The U.S.

New FDA Gudiances for August 2020 and Upcoming Advisory Committee Meetings

CATO Research

Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation: Draft Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders – Draft Guidance. Evaluating Cancer Drugs in Patients with Central Nervous System Metastases: Draft Guidance for Industry – Draft Guidance. By Dieanira Erudaitius, PhD, RAC, Regulatory Scientist, Regulatory Affairs at CATO SMS.

New FDA Gudiances for August 2020 and Upcoming Advisory Committee Meetings

CATO Research

Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation: Draft Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders – Draft Guidance. Evaluating Cancer Drugs in Patients with Central Nervous System Metastases: Draft Guidance for Industry – Draft Guidance. By Dieanira Erudaitius, PhD, RAC, Regulatory Scientist, Regulatory Affairs at CATO SMS.

Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences

The Pharma Data

Ion channels represent a large but under-exploited class of drug targets beyond G protein-coupled proteins (GPCRs). Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy

The Pharma Data

VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI ( dostarlimab-gxly ). Endometrial cancer is the most common gynecologic cancer in the U.S. and the fourth most common cancer in women in North America. 2 In addition, about 90,000 women globally die from endometrial cancer each year. MMR deficiency is most common in endometrial cancer.

DNA 40

CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) Published in Science Translational Medicine

The Pharma Data

CytoDel” or “the Company”), a privately-held corporation, today announces the publication of preclinical data on the Company’s lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine.

Innovative Companies Diving into The Neuro Market Ahead of 2021

The Pharma Data

Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc., in a statement. . Genesis went public on December 2 in a round of $52 million Series A financing led by Rock Springs Capital.

Birinapant licensing; AvantGen, IGM pairs up for anti-SARS-CoV-2 antibodies; BeiGene, Novartis to co-dvelop Tislelizumab; Valo raises USD190 M; Bluebird Bio Spins-off

Delveinsight

Birinapant is a clinical-stage SMAC mimetic that degrades Inhibitors of Apoptosis Proteins (IAPs) by binding to them, ultimately leading to cell death in tumor cells. Besides, BeiGene has an option to co-detail the product in North America, which will be funded in part by Novartis.

Researchers Discover Genetic Errors and Rogue Antibodies in Cases of Severe COVID-19 Infection

XTalks

The two studies were recently published online in the journal Science, both of which were led by Jean-Laurent Casanova, an infectious disease geneticist at Rockefeller University. Related: Low T Cell Counts Observed in COVID-19 Patients. Mutational Errors in COVID-19 Patients.

Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines

The Pharma Data

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. This test can also help in the determination of seroprevalence (i.e.

Angelman Syndrome Market: Insights Into The Recent Late-Stage Drug Failures And Novel Approaches To Treating This Rare Neurogenetic Disorder

Delveinsight

The first sign of a child suffering from Angelman syndrome is a delay in development, such as the inability to sit without support or making incoherent babbling sounds. Several pharmaceutical and biotech companies in the Angelman syndrome market are exploring the novel curative approaches.

Gene 52

Best OINTMENT or CREAM for insect bites

Druggist

For many customers, ointment or cream for insect bites is the first line of rescue in stings management. In this post, I will review the best ointment or cream for insect bites available over the counter and from pharmacies. The main active ingredient found in After Bite pen is ammonia.

Evotec Expands Oxfordshire Site into a Fully-Integrated R&D Centre Named ‘Dorothy Crowfoot Hodgkin Campus’

The Pharma Data

ADDS IN VITRO PHARMACOLOGY AND EXPANDS PROTEIN SCIENCES. HAMBURG, GERMANY / ACCESSWIRE / November 12, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the expansion of the Company’s existing campus based at Milton Park in Abingdon, Oxfordshire, UK, into a major, fully-integrated, co-located discovery and development centre to be named Dorothy Crowfoot Hodgkin Campus.

AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development

The Pharma Data

Using its novel yeast display system and large diverse human antibody libraries, AvantGen has identified a panel of high affinity human monoclonal antibody clones that bind to two distinct epitopes on the receptor binding domain of the SARS-CoV-2 spike protein. 11, 2021 23:59 UTC.

Clover biopharmaceuticals raises $230 M; BrainStorm after ALS; BARDA grants $5.65 M LightDeck for SARS-CoV-2 antigen test; Libtayo for first-line advanced NSCLC subset

Delveinsight

Clover Biopharmaceuticals is a clinical-stage biotechnology company based in China. The company plans to use the capital to expand its pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag technology platform.

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in.

The Pharma Data

The trial accrued 25 cases of symptomatic COVID-19 at the primary analysis.There were no cases of severe COVID-19 or COVID-19-related deaths in those treated with AZD7442. In the placebo arm, there were three cases of severe COVID-19, which included two deaths.

LumiraDx Receives SARS-CoV-2 Antigen Test Authorization in Japan and Brazil; Italy Recommends Expansion of Microfluidic Antigen Testing

The Pharma Data

With approvals in Japan and Brazil , the fast, accurate LumiraDx SARS-CoV-2 Antigen Test is now available to patients in more than 30 nations worldwide. In order to achieve authorization, LumiraDx conducted several studies and underwent an audit by the regulatory authorities.

Clinical Catch-Up: January 11-15 | BioSpace

The Pharma Data

The year is starting to pick up in terms of clinical trial announcements. Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days.

Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59

The Pharma Data

The Part I of the trial enrolled 327 patients with mild-to-moderate symptoms of COVID-19 across three treatment groups (40mg/kg, 80mg/kg and placebo), in which approximately 60% of patients with moderate symptoms suffered from COVID-19 related pneumonia. days earlier than those in the placebo group [5.4 In addition, CT-P59 treated patients rapidly and significantly reduced viral load through Day 7 compared to placebo. 13, 2021 09:39 UTC.

Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer

The Pharma Data

Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study. This approval marks Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the EU.

HR 52

Roche announces results from Evrysdi

The Pharma Data

Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine. In addition, 90% (19/21) of infants were alive without permanent ventilation after 12 months of treatment with Evrysdi.

Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19

The Pharma Data

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. AZD7442 was well tolerated in the trial.

Abionic Launches First Covid-19 Severity Test to Triage Patients Quickly and Accurately

The Pharma Data

BIOPÔLE LAUSANNE, Switzerland–( BUSINESS WIRE )– Abionic SA, a Swiss Medtech firm based in Lausanne, has developed the cSOFA score, a tool to assess the severity of Covid-19. In order to obtain the cSOFA score, a 30 ul drop of capillary blood is sufficient.

Clinical Catch-Up: January 18-22 | BioSpace

The Pharma Data

Gritstone Oncology , based in Emeryville, California, announced that it is advancing development of its own second-generation vaccine against COVID-19. Innovation Pharmaceuticals received the greenlight from the FDA to initiate a Phase II trial of Brilacidin in hospitalized COVID-19 patients.

BD Receives Order from Dutch Ministry of Health for More than Nine Million 15-minute COVID-19 Antigen Tests

The Pharma Data

million SARS-CoV-2 Assays for use on the BD Veritor Plus System to be delivered in The Netherlands by mid-November. million of its rapid, point-of-care, SARS-CoV-2 antigen tests for use on the BD Veritor Plus System, which detects SARS-CoV-2 in symptomatic patients in approximately 15 minutes.

The ‘failure’ of clinical trials in the search for COVID-19 treatments

Pharma Phorum

It may not be appropriate to use the word ‘failure’ when summarising the utility of clinical trials in the search for a curative or preventative treatment for disease. million worldwide and continues to increase despite the global public health measures that have been put in place.